Revenue remained stable in 2025, but net loss narrowed significantly year-over-year. Major impairment losses from terminated R&D projects and inventory risks were key factors, while no dividends were declared due to ongoing losses.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.